within Pharmacolibrary.Drugs.ATC.L;

model L04AG14
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.616666666666667e-06,
    adminDuration  = 600,
    adminMass      = 450 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.00365,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00248,
    k12             = 0.426,
    k21             = 0.426
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AG14</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ublituximab is a chimeric anti-CD20 monoclonal antibody developed for the treatment of relapsing forms of multiple sclerosis (MS). It works by depleting B cells, which play a role in the pathogenesis of MS. Ublituximab is approved for the treatment of relapsing forms of MS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with relapsing multiple sclerosis based on typical monoclonal antibody characteristics and public regulatory documents.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AG14;
